Markets:

Overview

News

Currencies

International

Treasuries

Ovid Therapeutics Inc. - Common Stock (NQ:OVID)

2.165 +0.005 (+0.23%)

Delayed Quote Updated: 11:54 AM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ovid Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm

August 01, 2024

From The Schall Law Firm

Via Business Wire

Ovid Therapeutics to Present at Upcoming August Investor Conferences

July 30, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

The Latest Analyst Ratings For Ovid Therapeutics ↗

July 26, 2024

Via Benzinga

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

July 23, 2024

Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the Brain

From Ovid Therapeutics Inc.

Via GlobeNewswire

Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts ↗

June 18, 2024

Via Benzinga

7 Sorry Biotech Stocks Set to Make Investors Sad ↗

July 22, 2024

Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell.

Via InvestorPlace

eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures

July 10, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

July 01, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics ↗

May 07, 2024

Via Benzinga

Nasdaq Surges Over 200 Points; Aaron's Shares Jump ↗

June 17, 2024

Via Benzinga

Is the Stock Market Closed on Juneteenth 2024? ↗

June 17, 2024

Investors wondering if the stock market is closed on Juneteenth 2024 have come to the right place as we have an answer to that question!

Via InvestorPlace

ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation ↗

June 17, 2024

Archer Aviation stock is down on Monday after the company alerted ACHR investors to a new MOU signed with Signature Aviation.

Via InvestorPlace

Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 17, 2024

Via Benzinga

AAN Stock Alert: The Aaron’s Company Pops 33% on Take-Private Deal ↗

June 17, 2024

The Aaron's Company stock is up on Monday after it announced a take-private deal that values AAN shares at $10.10 each.

Via InvestorPlace

Why Is Ovid Therapeutics (OVID) Stock Down 69% Today? ↗

June 17, 2024

Ovid Therapeutics stock is down on Monday with heavy trading of OVID shares after the company reported a failed Phase3 clinical trial.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 17, 2024

Via Benzinga

Crude Oil Rises 1%; Mustang Bio Shares Spike Higher ↗

June 17, 2024

Via Benzinga

US Stocks Mixed; Dow Tumbles Over 100 Points ↗

June 17, 2024

Via Benzinga

Topics Stocks

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail? ↗

June 17, 2024

Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug.

Via Benzinga

Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗

June 17, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 17, 2024

Via Benzinga

Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat

June 17, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

3 Sorry Penny Stocks to Sell in May While You Still Can ↗

May 28, 2024

Steer clear of these three penny stocks to sell that are plagued by financial instability and mounting losses.

Via InvestorPlace

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024 ↗

May 20, 2024

Although the concept of penny stocks to buy is extremely risky, these ideas have the advantage of analysts’ positive assessments.

Via InvestorPlace

OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 14, 2024

OVID stock results show that Ovid Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

May 14, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 24, 2024

Via Benzinga

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 04, 2024

From Ovid Therapeutics Inc.

Via GlobeNewswire

Over $2M Bet On NextNav? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying ↗

March 21, 2024

The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.